%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Yang Cao, Qing Ye, Mengfei Zhuang, Shuwu Xie, Ruihua Zhong, Jingang Cui, Jieyun Zhou, Yan Zhu, Tingting Zhang, Lin Cao
Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K/Akt/mTOR signaling pathway
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 11 0 R/Annots 12 0 R/Contents 13 0 R/TrimBox[0 0 612 792]>>
endobj
12 0 obj
[14 0 R 15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R]
endobj
14 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref001)>>
endobj
15 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref002)>>
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref003)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref004)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref005)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref006)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref007)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref008)>>
endobj
22 0 obj
<>/Border[0 0 0]/A 23 0 R>>
endobj
23 0 obj
<>
endobj
13 0 obj
[24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R 32 0 R 33 0 R]
endobj
24 0 obj
<>stream
q
0.45 0.36 0.35 0.01 k
0 w
575.9997 547.1144 m
199.9998 547.1144 l
199.9998 547.6144 l
575.9997 547.6144 l
f*
0.83 0.64 0.02 0 k
438.2362 445.9465 m
442.9984 445.9465 l
h
f*
439.3701 393.9024 m
444.1323 393.9024 l
h
f*
388.4598 380.9197 m
393.222 380.9197 l
h
f*
385.7953 315.9496 m
390.5575 315.9496 l
h
f*
203.5276 250.9228 m
208.4031 250.9228 l
h
f*
203.5276 198.9354 m
208.4031 198.9354 l
h
f*
316.5732 159.9307 m
321.3354 159.9307 l
h
f*
306.0283 94.9039 m
310.7906 94.9039 l
h
f*
0 g
1 j
1 J
9.5 0 0 9.5 200.0125 707.7543 cm
BT
/F0 1 Tf
1 TL
-0.0147 Tc
0 0 Td
(and)Tj
1.832 0 Td
(Western)Tj
3.8432 0 Td
(Blotting)Tj
3.4314 0 Td
(assays)Tj
3.2404 0 Td
(confirmed)Tj
4.4698 0 Td
(that)Tj
1.8261 0 Td
(the)Tj
1.5635 0 Td
(expression)Tj
4.8935 0 Td
(of)Tj
1.0264 0 Td
(VEGF,)Tj
3.1629 0 Td
(p-Akt,)Tj
2.7451 0 Td
(and)Tj
1.8381 0 Td
(p-mTOR)Tj
-33.8724 -1.474 Td
(was)Tj
1.9454 0 Td
(down-regu)Tj
4.5772 0 Td
(lated)Tj
2.3035 0 Td
(in)Tj
0.9608 0 Td
(ginsenoside)Tj
5.3709 0 Td
(Rg3)Tj
1.9992 0 Td
(-treated)Tj
3.5447 0 Td
(lesions.)Tj
3.4852 0 Td
(Real-time)Tj
4.3504 0 Td
(PCR)Tj
2.2856 0 Td
(results)Tj
3.0614 0 Td
(also)Tj
1.9813 0 Td
(showed)Tj
-35.8656 -1.474 Td
(that)Tj
1.8261 0 Td
(the)Tj
1.5635 0 Td
(mRNA)Tj
3.1032 0 Td
(expression)Tj
4.8934 0 Td
(levels)Tj
2.6795 0 Td
(of)Tj
1.0265 0 Td
(VEGF,)Tj
3.1568 0 Td
(Akt,)Tj
1.8978 0 Td
(and)Tj
1.832 0 Td
(mTOR)Tj
3.1151 0 Td
(in)Tj
0.9608 0 Td
(the)Tj
1.5636 0 Td
(ectopic)Tj
3.2762 0 Td
(endometrium)Tj
5.8781 0 Td
(were)Tj
-36.7726 -1.474 Td
(reduced.)Tj
ET
Q
q
1 j
1 J
0 w
11.4998 0 0 11.4998 200.0125 633.6 cm
BT
/F2 1 Tf
1 TL
-0.0035 Tc
0 0 Td
(Conclusions)Tj
ET
Q
q
1 j
1 J
0 w
9.5 0 0 9.5 200.0125 616.5921 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(The)Tj
1.9275 0 Td
(present)Tj
3.5209 0 Td
(study)Tj
2.584 0 Td
(demonstrate)Tj
5.5082 0 Td
(s,)Tj
0.9906 0 Td
(for)Tj
1.3785 0 Td
(the)Tj
1.5934 0 Td
(first)Tj
1.8142 0 Td
(time,)Tj
2.3691 0 Td
(that)Tj
1.8739 0 Td
(ginsenoside)Tj
5.4842 0 Td
(Rg3)Tj
2.035 0 Td
(suppresses)Tj
5.2754 0 Td
(angio-)Tj
-36.3549 -1.474 Td
(genesis)Tj
3.6223 0 Td
(in)Tj
0.9847 0 Td
(developing)Tj
4.983 0 Td
(endometrial)Tj
5.3828 0 Td
(lesions.)Tj
3.5687 0 Td
(The)Tj
1.9275 0 Td
(ginsenoside)Tj
5.4843 0 Td
(Rg3)Tj
2.029 0 Td
(inhibitory)Tj
4.1654 0 Td
(effect)Tj
2.6437 0 Td
(on)Tj
1.3188 0 Td
(the)Tj
-36.1102 -1.468 Td
(growth)Tj
3.1867 0 Td
(of)Tj
1.0443 0 Td
(the)Tj
1.5993 0 Td
(ectopic)Tj
3.3479 0 Td
(endometrium)Tj
5.9975 0 Td
(in)Tj
0.9847 0 Td
(EMs)Tj
2.208 0 Td
(rats)Tj
1.8738 0 Td
(might)Tj
2.6377 0 Td
(occur)Tj
2.6437 0 Td
(through)Tj
3.5687 0 Td
(the)Tj
1.5933 0 Td
(blocking)Tj
3.8372 0 Td
(of)Tj
1.0503 0 Td
(the)Tj
-35.5731 -1.474 Td
(VEGFR-2-mediate)Tj
8.1577 0 Td
(d)Tj
0.7699 0 Td
(PI3K/Akt/mTOR)Tj
7.2984 0 Td
(signaling)Tj
4.1058 0 Td
(pathway,)Tj
4.1833 0 Td
(thus)Tj
2.0887 0 Td
(halting)Tj
3.121 0 Td
(angiogenesis)Tj
6.0333 0 Td
(and)Tj
1.8679 0 Td
(pro-)Tj
-37.626 -1.474 Td
(moting)Tj
3.1867 0 Td
(the)Tj
1.5933 0 Td
(apoptosis)Tj
4.4519 0 Td
(of)Tj
1.0444 0 Td
(ectopic)Tj
3.3538 0 Td
(endometrial)Tj
5.3768 0 Td
(cells.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 489.9968 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 472.9889 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Endometriosis\(EMs\)is)Tj
9.1785 0 Td
(a)Tj
0.6519 0 Td
(frequent)Tj
3.6114 0 Td
(disease,)Tj
3.2428 0 Td
(which)Tj
2.6475 0 Td
(affects)Tj
2.7383 0 Td
(at)Tj
0.9524 0 Td
(least)Tj
1.9842 0 Td
(10%)Tj
1.9276 0 Td
(of)Tj
1.0148 0 Td
(women)Tj
3.2031 0 Td
(during)Tj
2.9253 0 Td
(their)Tj
-34.0778 -1.2982 Td
(reproductive)Tj
5.3291 0 Td
(life.)Tj
1.6724 0 Td
(The)Tj
1.7801 0 Td
(incidence)Tj
4.0762 0 Td
(of)Tj
1.0148 0 Td
(EMs)Tj
2.041 0 Td
(among)Tj
2.9933 0 Td
(infertile)Tj
3.3562 0 Td
(women)Tj
3.2031 0 Td
(is)Tj
0.8504 0 Td
(approximately)Tj
5.9754 0 Td
(40%.)Tj
2.1487 0 Td
(Of)Tj
1.2586 0 Td
(the)Tj
-35.6993 -1.2983 Td
(affected)Tj
3.3278 0 Td
(women,)Tj
3.4242 0 Td
(approximately)Tj
5.9754 0 Td
(90%)Tj
1.9276 0 Td
(experience)Tj
4.507 0 Td
(pelvic)Tj
2.5569 0 Td
(pain[)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(].)Tj
3.3675 0 Td
(EMs)Tj
2.0409 0 Td
(is)Tj
0.8504 0 Td
(known)Tj
3.0047 0 Td
(to)Tj
1.0262 0 Td
(be)Tj
1.1452 0 Td
(the)Tj
1.474 0 Td
(pri-)Tj
-34.6278 -1.3039 Td
(mary)Tj
2.296 0 Td
(cause)Tj
2.3924 0 Td
(of)Tj
1.0148 0 Td
(dysmenorrhea,)Tj
6.2135 0 Td
(pelvic)Tj
2.5512 0 Td
(pain,)Tj
2.2167 0 Td
(and)Tj
1.7291 0 Td
(infertility.)Tj
4.1726 0 Td
(Although)Tj
4.0081 0 Td
(EMs)Tj
2.041 0 Td
(is)Tj
0.8503 0 Td
(a)Tj
0.652 0 Td
(benign)Tj
2.982 0 Td
(lesion,)Tj
2.795 0 Td
(its)Tj
-35.9147 -1.2983 Td
(invasive)Tj
3.4242 0 Td
(nature,)Tj
3.05 0 Td
(the)Tj
1.4627 0 Td
(rate)Tj
1.7461 0 Td
(of)Tj
1.0092 0 Td
(metastasis)Tj
4.2746 0 Td
(and)Tj
1.7291 0 Td
(recurrence)Tj
4.5241 0 Td
(are)Tj
1.4456 0 Td
(typical)Tj
2.863 0 Td
(of)Tj
1.0091 0 Td
(a)Tj
0.652 0 Td
(clinically)Tj
3.7757 0 Td
(malignant)Tj
4.2746 0 Td
(lesion)Tj
-35.24 -1.2982 Td
(and)Tj
1.7291 0 Td
(thus,)Tj
2.16 0 Td
(it)Tj
0.788 0 Td
(has)Tj
1.542 0 Td
(been)Tj
2.1203 0 Td
(generally)Tj
3.8324 0 Td
(referred)Tj
3.4243 0 Td
(to)Tj
1.0204 0 Td
(as)Tj
1.0148 0 Td
(benign)Tj
2.9821 0 Td
(cancer.)Tj
3.067 0 Td
(The)Tj
1.7858 0 Td
(5-year)Tj
2.727 0 Td
(recurrence)Tj
4.5297 0 Td
(rate)Tj
1.7461 0 Td
(of)Tj
1.0148 0 Td
(EMs)Tj
-35.4838 -1.3039 Td
(is)Tj
0.839 0 Td
(above)Tj
2.5398 0 Td
(40%,)Tj
2.143 0 Td
(whether)Tj
3.4696 0 Td
(treated)Tj
2.9934 0 Td
(with)Tj
1.9899 0 Td
(surgery)Tj
3.1861 0 Td
(or)Tj
1.0885 0 Td
(drug)Tj
2.1089 0 Td
(therapy)Tj
3.2372 0 Td
([)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
(],)Tj
1.5931 0 Td
(and)Tj
1.7234 0 Td
(the)Tj
1.4627 0 Td
(cancer)Tj
2.8346 0 Td
(occurs)Tj
2.829 0 Td
(clinically)Tj
-34.0382 -1.2983 Td
(in)Tj
1.0318 0 Td
(0.7)Tj
1.4003 0 Td
(to)Tj
1.0261 0 Td
(1.6%)Tj
2.1543 0 Td
(of)Tj
1.0148 0 Td
(patients)Tj
3.3675 0 Td
(in)Tj
1.0319 0 Td
(a)Tj
0.6576 0 Td
(8-year)Tj
2.7269 0 Td
(follow-up)Tj
4.0932 0 Td
([)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(].)Tj
1.6044 0 Td
(The)Tj
1.7801 0 Td
(exact)Tj
2.2677 0 Td
(pathogenesis)Tj
5.3518 0 Td
(of)Tj
1.0148 0 Td
(EMs)Tj
2.041 0 Td
(is)Tj
0.8503 0 Td
(not)Tj
1.5761 0 Td
(clear,)Tj
-34.9906 -1.2983 Td
(with)Tj
1.9955 0 Td
(most)Tj
2.2054 0 Td
(scholars)Tj
3.4525 0 Td
(recognizing)Tj
4.921 0 Td
(Sampson's)Tj
4.456 0 Td
(Theory)Tj
3.1181 0 Td
(of)Tj
1.0148 0 Td
(Implantation)Tj
5.4765 0 Td
(of)Tj
1.0148 0 Td
(Endometriosis,)Tj
6.2758 0 Td
(which)Tj
-33.9304 -1.3039 Td
(postulates)Tj
4.1952 0 Td
(that)Tj
1.7745 0 Td
(EMs)Tj
2.0466 0 Td
(is)Tj
0.8447 0 Td
(caused)Tj
2.9197 0 Td
(by)Tj
1.1792 0 Td
(backflow)Tj
3.8097 0 Td
(menstruation.)Tj
5.8507 0 Td
(It)Tj
0.856 0 Td
(is)Tj
0.8504 0 Td
(generally)Tj
3.8324 0 Td
(accepted)Tj
3.6907 0 Td
(that)Tj
1.7802 0 Td
(the)Tj
1.4683 0 Td
(for-)Tj
-35.0983 -1.2983 Td
(mation)Tj
3.0954 0 Td
(and)Tj
1.7291 0 Td
(growth)Tj
3.0727 0 Td
(of)Tj
1.0148 0 Td
(ectopic)Tj
3.0784 0 Td
(lesions)Tj
2.9367 0 Td
(require)Tj
3.1124 0 Td
(the)Tj
1.4684 0 Td
(supply)Tj
2.8459 0 Td
(of)Tj
1.0148 0 Td
(oxygen)Tj
3.0841 0 Td
(and)Tj
1.7291 0 Td
(nutrients.)Tj
4.0876 0 Td
(Studies)Tj
3.101 0 Td
(have)Tj
-35.3704 -1.2982 Td
(indicated)Tj
3.9344 0 Td
(that)Tj
1.7802 0 Td
(angiogenesis)Tj
5.2894 0 Td
(is)Tj
0.8504 0 Td
(an)Tj
1.2018 0 Td
(important)Tj
4.2803 0 Td
(feature)Tj
2.9877 0 Td
(of)Tj
1.0148 0 Td
(EMs,)Tj
2.2677 0 Td
(however,)Tj
3.8381 0 Td
(the)Tj
1.4684 0 Td
(underlying)Tj
4.6034 0 Td
(mecha-)Tj
-33.5166 -1.2983 Td
(nism)Tj
2.2166 0 Td
(of)Tj
1.0148 0 Td
(angiogenesis)Tj
5.2894 0 Td
(in)Tj
1.0375 0 Td
(EMs)Tj
2.0409 0 Td
(remains)Tj
3.447 0 Td
(unclear)Tj
3.1917 0 Td
([)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(].)Tj
0.009 Tc
-17.0417 -1.3039 Td
(The)Tj
1.8255 0 Td
(treatment)Tj
4.2519 0 Td
(of)Tj
1.0375 0 Td
(EMs)Tj
2.0863 0 Td
(is)Tj
0.873 0 Td
(mainly)Tj
3.0671 0 Td
(based)Tj
2.5398 0 Td
(on)Tj
1.2983 0 Td
(surgery)Tj
3.2882 0 Td
(and)Tj
1.7688 0 Td
(drug)Tj
2.1656 0 Td
(therapy.)Tj
3.5773 0 Td
(Surgery)Tj
3.3959 0 Td
(can)Tj
1.6668 0 Td
(remove)Tj
-34.0382 -1.2983 Td
(ectopic)Tj
3.1691 0 Td
(foci,)Tj
1.9955 0 Td
(recover)Tj
3.2882 0 Td
(normal)Tj
3.2258 0 Td
(pelvic)Tj
2.6306 0 Td
(anatomy,)Tj
4.0421 0 Td
(relieve)Tj
2.9197 0 Td
(pain,)Tj
2.279 0 Td
(and)Tj
1.7688 0 Td
(increase)Tj
3.5773 0 Td
(the)Tj
1.5081 0 Td
(chances)Tj
3.4525 0 Td
(of)Tj
1.0432 0 Td
(preg-)Tj
-34.8999 -1.2982 Td
(nancy.)Tj
2.931 0 Td
(Drug)Tj
2.3754 0 Td
(therapy)Tj
3.3335 0 Td
(aims)Tj
2.1543 0 Td
(to)Tj
1.0545 0 Td
(inhibit)Tj
2.9934 0 Td
(the)Tj
1.508 0 Td
(ovarian)Tj
3.3278 0 Td
(hormone)Tj
4.0139 0 Td
(secretion,)Tj
4.2009 0 Td
(but)Tj
1.593 0 Td
(the)Tj
1.5081 0 Td
(effect)Tj
2.4434 0 Td
(is)Tj
0.8731 0 Td
(short-)Tj
-34.3103 -1.3039 Td
(lived)Tj
2.2053 0 Td
(and)Tj
1.7688 0 Td
(has)Tj
1.5817 0 Td
(side)Tj
1.8482 0 Td
(effects)Tj
2.8176 0 Td
(such)Tj
2.1147 0 Td
(as)Tj
1.0374 0 Td
(the)Tj
1.508 0 Td
(onset)Tj
2.4265 0 Td
(of)Tj
1.0375 0 Td
(menopausal)Tj
5.1703 0 Td
(symptoms)Tj
4.4617 0 Td
(and)Tj
1.7688 0 Td
(osteoporosis)Tj
-29.7465 -1.2983 Td
([)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
(].)Tj
1.6497 0 Td
(Regardless)Tj
4.5864 0 Td
(of)Tj
1.0432 0 Td
(treatment,)Tj
4.49 0 Td
(EMs)Tj
2.0806 0 Td
(has)Tj
1.5818 0 Td
(a)Tj
0.6689 0 Td
(high)Tj
2.058 0 Td
(recurrence)Tj
4.6601 0 Td
(rate.)Tj
2.0353 0 Td
(Therefore,)Tj
4.524 0 Td
(new)Tj
1.9162 0 Td
(treatments)Tj
4.6262 0 Td
(for)Tj
-35.9204 -1.2983 Td
(EMs)Tj
2.0806 0 Td
(aimed)Tj
2.7552 0 Td
(at)Tj
0.9808 0 Td
(reducing)Tj
3.8778 0 Td
(the)Tj
1.508 0 Td
(recurrence)Tj
4.6601 0 Td
(rate)Tj
1.7972 0 Td
(and)Tj
1.7688 0 Td
(recovering)Tj
4.6091 0 Td
(fertility)Tj
3.2485 0 Td
(have)Tj
2.1146 0 Td
(become)Tj
3.4016 0 Td
(a)Tj
0.6689 0 Td
(current)Tj
-33.4712 -1.3039 Td
(focus)Tj
2.3924 0 Td
(on)Tj
1.2982 0 Td
(EMs)Tj
2.0863 0 Td
(research.)Tj
3.8948 0 Td
(Recent)Tj
3.0387 0 Td
(studies)Tj
3.0784 0 Td
(investigated)Tj
5.142 0 Td
(the)Tj
1.5081 0 Td
(molecular)Tj
4.3369 0 Td
(mechanism)Tj
4.9606 0 Td
(of)Tj
1.0432 0 Td
(EMs)Tj
2.0806 0 Td
(and)Tj
-34.8602 -1.2983 Td
(have)Tj
2.1089 0 Td
(provided)Tj
3.9231 0 Td
(new)Tj
1.9162 0 Td
(treatment)Tj
4.252 0 Td
(possibilities,)Tj
5.2781 0 Td
(especially)Tj
4.1442 0 Td
(focused)Tj
3.3732 0 Td
(on)Tj
1.2983 0 Td
(anti-angiogenesis)Tj
7.4097 0 Td
(strategies)Tj
-33.7037 -1.2982 Td
([)Tj
0.83 0.64 0.02 0 k
(6)Tj
0 g
(].)Tj
-0.004 Tc
1.1962 -1.3039 Td
(After)Tj
2.2903 0 Td
(menstrual)Tj
4.2463 0 Td
(blood)Tj
2.5172 0 Td
(anarrhea)Tj
3.7643 0 Td
(into)Tj
1.8426 0 Td
(the)Tj
1.4683 0 Td
(abdominal)Tj
4.5071 0 Td
(cavity,)Tj
2.7779 0 Td
(the)Tj
1.474 0 Td
(growth)Tj
3.0727 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(ectopic)Tj
3.0784 0 Td
(endo-)Tj
-34.7185 -1.2983 Td
(metrium)Tj
3.7473 0 Td
(requires)Tj
3.4696 0 Td
(adequate)Tj
3.7984 0 Td
(nutrient)Tj
3.5036 0 Td
(supply;)Tj
3.0671 0 Td
(therefore)Tj
3.8551 0 Td
(neovascularization)Tj
7.6875 0 Td
(is)Tj
0.8447 0 Td
(key)Tj
1.5987 0 Td
(to)Tj
1.0262 0 Td
(the)Tj
1.4683 0 Td
(survival)Tj
-34.0665 -1.2983 Td
(of)Tj
1.0147 0 Td
(the)Tj
1.4684 0 Td
(ectopic)Tj
3.0784 0 Td
(endometrium)Tj
5.7543 0 Td
([)Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(].)Tj
1.6044 0 Td
(Vascular)Tj
3.7133 0 Td
(endothelial)Tj
4.6658 0 Td
(growth)Tj
3.0728 0 Td
(factor)Tj
2.5455 0 Td
(\(VEGF\),)Tj
3.634 0 Td
(the)Tj
1.4683 0 Td
(strongest)Tj
-32.0199 -1.2982 Td
(angiogenic)Tj
4.5694 0 Td
(factor,)Tj
2.7666 0 Td
(can)Tj
1.627 0 Td
(specifically)Tj
4.5695 0 Td
(combine)Tj
3.719 0 Td
(with)Tj
1.9956 0 Td
(vascular)Tj
3.4752 0 Td
(endothelium)Tj
5.3348 0 Td
(to)Tj
1.0261 0 Td
(promote)Tj
3.6624 0 Td
(endothelial)Tj
-32.7456 -1.304 Td
(proliferation)Tj
5.2667 0 Td
(and)Tj
1.7291 0 Td
(angiogenesis)Tj
5.2894 0 Td
(and)Tj
1.7348 0 Td
(can)Tj
1.6214 0 Td
(increase)Tj
3.4753 0 Td
(vascular)Tj
3.4696 0 Td
(permeability.)Tj
5.4765 0 Td
(Some)Tj
2.4434 0 Td
(studies)Tj
2.9877 0 Td
(indicate)Tj
-33.4939 -1.2982 Td
(that)Tj
1.7744 0 Td
(anti-VEGF/VEGFR)Tj
8.0844 0 Td
(agents)Tj
2.7552 0 Td
(appeared)Tj
3.8665 0 Td
(to)Tj
1.0261 0 Td
(inhibit)Tj
2.9027 0 Td
(the)Tj
1.4683 0 Td
(growth)Tj
3.0727 0 Td
(of)Tj
1.0148 0 Td
(endometriosis,)Tj
6.1285 0 Td
(with)Tj
1.9956 0 Td
(no)Tj
-34.0892 -1.2983 Td
(effect)Tj
2.3527 0 Td
(on)Tj
1.2699 0 Td
(ovarian)Tj
3.2258 0 Td
(function,)Tj
3.8494 0 Td
(and)Tj
1.7178 0 Td
(therefore)Tj
3.8438 0 Td
(anti-angiogenic)Tj
6.4629 0 Td
(therapy)Tj
3.2372 0 Td
(may)Tj
1.9218 0 Td
(become)Tj
3.3109 0 Td
(a)Tj
0.6463 0 Td
(future)Tj
2.6475 0 Td
(strategy)Tj
-34.486 -1.3039 Td
(in)Tj
1.0318 0 Td
(treating)Tj
3.3278 0 Td
(endometriosis)Tj
5.9017 0 Td
([)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(].)Tj
1.6044 0 Td
(VEGF)Tj
2.7269 0 Td
(and)Tj
1.7291 0 Td
(its)Tj
1.1452 0 Td
(receptor-mediated)Tj
7.6308 0 Td
(signal)Tj
2.5399 0 Td
(transduction)Tj
5.3347 0 Td
(pathways)Tj
-32.9723 -1.2983 Td
(play)Tj
1.8708 0 Td
(an)Tj
1.2019 0 Td
(important)Tj
4.2803 0 Td
(role)Tj
1.7688 0 Td
(in)Tj
1.0375 0 Td
(physiological)Tj
5.4424 0 Td
(and)Tj
1.7292 0 Td
(pathological)Tj
5.0966 0 Td
(angiogenesis.)Tj
5.5162 0 Td
(Among)Tj
3.2428 0 Td
(them,)Tj
2.5172 0 Td
(the)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 416.6362 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Ginsen)Tj
3.111 0 Td
(oside)Tj
2.5654 0 Td
(Rg3)Tj
2.0197 0 Td
(inhibits)Tj
3.2669 0 Td
(angiogenes)Tj
5.067 0 Td
(is)Tj
0.9284 0 Td
(in)Tj
0.9779 0 Td
(EMs)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01865)Tj
4.089 0 Td
(20)Tj
0 g
2.0906 0 Td
(November)Tj
4.7622 0 Td
(15,)Tj
1.5875 0 Td
(2017)Tj
32.5561 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(16)Tj
/F9 1 Tf
-0.025 Tc
-66.402 84.0904 Td
(design,)Tj
2.8984 0 Td
(data)Tj
1.7929 0 Td
(collection)Tj
3.7418 0 Td
(and)Tj
1.5874 0 Td
(analysis,)Tj
3.4087 0 Td
(decision)Tj
3.2953 0 Td
(to)Tj
-16.7245 -1.3748 Td
(publish,)Tj
3.1464 0 Td
(or)Tj
0.9993 0 Td
(preparation)Tj
4.4433 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
1.3677 0 Td
(manuscript.)Tj
/F8 1 Tf
-10.9063 -2.126 Td
(Competing)Tj
4.3795 0 Td
(interests)Tj
3.3307 0 Td
(:)Tj
/F9 1 Tf
0.4819 0 Td
(The)Tj
1.5875 0 Td
(authors)Tj
3.0401 0 Td
(have)Tj
1.963 0 Td
(declared)Tj
-14.7827 -1.3749 Td
(that)Tj
1.6228 0 Td
(no)Tj
1.1693 0 Td
(competing)Tj
4.1599 0 Td
(interests)Tj
ET
endstream
endobj
25 0 obj
<>stream
endstream
endobj
26 0 obj
<>stream
endstream
endobj
27 0 obj
<>stream
endstream
endobj
28 0 obj
<>stream
endstream
endobj
29 0 obj
<>stream
endstream
endobj
30 0 obj
<>stream
endstream
endobj
31 0 obj
<>stream
endstream
endobj
32 0 obj
<>stream
endstream
endobj
33 0 obj
<>stream
BT
10.3394 79.2147 Td
(exist.)Tj
ET
Q
endstream
endobj
34 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 11 0 R/Annots 35 0 R/Contents 36 0 R/TrimBox[0 0 612 792]>>
endobj
35 0 obj
[37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R 44 0 R]
endobj
37 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref009)>>
endobj
38 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref010)>>
endobj
39 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref011)>>
endobj
40 0 obj
<>/Border[0 0 0]/A 45 0 R>>
endobj
45 0 obj
<>
endobj
41 0 obj
<>/Border[0 0 0]/A 46 0 R>>
endobj
46 0 obj
<>
endobj
42 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref012)>>
endobj
43 0 obj
<>/Border[0 0 0]/Dest(Rpone.0186520.ref013)>>
endobj
44 0 obj
<>/Border[0 0 0]/A 47 0 R>>
endobj
47 0 obj
<>
endobj
36 0 obj
[48 0 R 49 0 R 50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R]
endobj
48 0 obj
<>stream
q
0.83 0.64 0.02 0 k
393.8457 615.3449 m
398.6079 615.3449 l
h
f*
444.6425 355.3512 m
454.3937 355.3512 l
h
f*
255.7984 316.3465 m
265.6063 316.3465 l
h
f*
336.6425 120.926 m
555.7606 120.926 l
h
f*
200.0126 107.9433 m
229.8331 107.9433 l
h
f*
233.2346 107.9433 m
242.7591 107.9433 l
h
f*
321.6189 81.9213 m
331.1433 81.9213 l
h
f*
0 g
1 j
1 J
0 w
10 0 0 10 200.0125 707.4141 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(phosphatidylinositol)Tj
8.4075 0 Td
(3-kinase/protein)Tj
6.8371 0 Td
(kinase)Tj
2.7496 0 Td
(B/mammalian)Tj
5.9527 0 Td
(target)Tj
2.5115 0 Td
(of)Tj
1.0148 0 Td
(rapamycin)Tj
4.49 0 Td
(\(PI3K/Akt/)Tj
-31.9632 -1.3039 Td
(mTOR\))Tj
3.3561 0 Td
(signaling)Tj
3.8268 0 Td
(pathway)Tj
3.566 0 Td
(plays)Tj
2.2336 0 Td
(an)Tj
1.2019 0 Td
(important)Tj
4.286 0 Td
(role)Tj
1.7631 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(occurrence)Tj
4.6658 0 Td
(and)Tj
1.7292 0 Td
(development)Tj
5.4084 0 Td
(of)Tj
1.0148 0 Td
(a)Tj
-35.5575 -1.2982 Td
(variety)Tj
2.9196 0 Td
(of)Tj
1.0205 0 Td
(tumors.)Tj
3.3278 0 Td
(ThePI3K/Akt/mTOR)Tj
8.7704 0 Td
(pathway)Tj
3.5659 0 Td
(promotes)Tj
4.0252 0 Td
(tumor)Tj
2.7439 0 Td
(angiogenesis)Tj
5.2951 0 Td
(by)Tj
1.1792 0 Td
(altering)Tj
-32.8476 -1.2983 Td
(the)Tj
1.4683 0 Td
(activation)Tj
4.1499 0 Td
(state)Tj
2.0352 0 Td
(of)Tj
1.0148 0 Td
(a)Tj
0.6577 0 Td
(large)Tj
2.16 0 Td
(number)Tj
3.4185 0 Td
(of)Tj
1.0148 0 Td
(downstream)Tj
5.1931 0 Td
(effector)Tj
3.2428 0 Td
(molecules)Tj
4.2009 0 Td
(and)Tj
1.7291 0 Td
(inducing)Tj
3.7927 0 Td
(cell)Tj
1.5591 0 Td
(pro-)Tj
-35.6369 -1.2983 Td
(liferation)Tj
3.8721 0 Td
(and)Tj
1.7291 0 Td
(inhibiting)Tj
4.1839 0 Td
(apoptosis)Tj
3.9855 0 Td
(to)Tj
1.0261 0 Td
(further)Tj
3.0274 0 Td
(promote)Tj
3.668 0 Td
(tumor)Tj
2.7439 0 Td
(development.)Tj
5.6353 0 Td
(Activated)Tj
4.0308 0 Td
(mTOR)Tj
-33.9021 -1.3039 Td
(and)Tj
1.7291 0 Td
(other)Tj
2.347 0 Td
(kinases)Tj
3.1125 0 Td
(can)Tj
1.627 0 Td
(induce4E-BP1)Tj
5.9471 0 Td
(phosphorylation)Tj
6.8144 0 Td
(and)Tj
1.7292 0 Td
(reduce)Tj
2.914 0 Td
(the)Tj
1.474 0 Td
(affinity)Tj
3.0614 0 Td
(of)Tj
1.0148 0 Td
(4E-BP1)Tj
3.2314 0 Td
(and)Tj
-35.0019 -1.2982 Td
(elF-4E.)Tj
3.0387 0 Td
(Released)Tj
3.6793 0 Td
(elF-4E)Tj
2.812 0 Td
(combines)Tj
4.0762 0 Td
(with)Tj
2.0012 0 Td
(elF-4G,)Tj
3.1805 0 Td
(-4B,)Tj
1.8538 0 Td
(and)Tj
1.7291 0 Td
(-4A,)Tj
1.9559 0 Td
(and)Tj
1.7291 0 Td
(then)Tj
2.0183 0 Td
(translates)Tj
3.9968 0 Td
(encoded)Tj
-32.0709 -1.2983 Td
(cyclinD1,)Tj
4.0195 0 Td
(HIF1)Tj
2.33 0 Td
(alpha)Tj
2.3811 0 Td
(and,)Tj
1.9559 0 Td
(subsequently,)Tj
5.6296 0 Td
(VEGF)Tj
2.7269 0 Td
([)Tj
0.83 0.64 0.02 0 k
(9)Tj
0 g
(].)Tj
1.6044 0 Td
(This)Tj
1.9842 0 Td
(seems)Tj
2.6079 0 Td
(to)Tj
1.0261 0 Td
(indicate)Tj
3.4129 0 Td
(that)Tj
1.7745 0 Td
(not)Tj
1.576 0 Td
(only)Tj
1.9729 0 Td
(is)Tj
-35.0019 -1.3039 Td
(VEGF)Tj
2.7269 0 Td
(an)Tj
1.2018 0 Td
(activator)Tj
3.7077 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(PI3K/Akt)Tj
4.0762 0 Td
(signaling)Tj
3.8267 0 Td
(pathway,)Tj
3.7927 0 Td
(but)Tj
1.5534 0 Td
(also)Tj
1.7688 0 Td
(the)Tj
1.4684 0 Td
(activation)Tj
4.1555 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(PI3K/Akt)Tj
-33.2445 -1.2983 Td
(signaling)Tj
3.821 0 Td
(pathway)Tj
3.5717 0 Td
(is)Tj
0.8447 0 Td
(itself)Tj
2.1089 0 Td
(promoted)Tj
4.1896 0 Td
(by)Tj
1.1792 0 Td
(the)Tj
1.474 0 Td
(transcription)Tj
5.4312 0 Td
(of)Tj
1.0148 0 Td
(VEGF)Tj
2.7269 0 Td
(in)Tj
1.0375 0 Td
(a)Tj
0.6519 0 Td
(positive)Tj
3.3165 0 Td
(feedback)Tj
3.7418 0 Td
(loop.)Tj
-35.1097 -1.2983 Td
(At)Tj
1.2018 0 Td
(present,)Tj
3.3902 0 Td
(the)Tj
1.4684 0 Td
(inhibition)Tj
4.2236 0 Td
(of)Tj
1.0148 0 Td
(expression)Tj
4.4673 0 Td
(of)Tj
1.0148 0 Td
(PI3K,)Tj
2.4945 0 Td
(Akt)Tj
1.6951 0 Td
(and)Tj
1.7348 0 Td
(other)Tj
2.3471 0 Td
(related)Tj
2.9423 0 Td
(genes)Tj
2.4435 0 Td
(by)Tj
1.1792 0 Td
(gene)Tj
2.0806 0 Td
(knockout)Tj
-33.698 -1.3039 Td
(or)Tj
1.0941 0 Td
(small)Tj
2.3301 0 Td
(molecule)Tj
3.8381 0 Td
(drugs)Tj
2.4718 0 Td
(towards)Tj
3.4015 0 Td
(the)Tj
1.474 0 Td
(blocking)Tj
3.6794 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(activation)Tj
4.1556 0 Td
(of)Tj
1.0148 0 Td
(a)Tj
0.6519 0 Td
(variety)Tj
2.9254 0 Td
(of)Tj
1.0148 0 Td
(downstream)Tj
-30.5346 -1.2982 Td
(anti-effector)Tj
5.142 0 Td
(molecules,)Tj
4.422 0 Td
(the)Tj
1.4683 0 Td
(inhibition)Tj
4.2293 0 Td
(of)Tj
1.0148 0 Td
(angiogenesis)Tj
5.2894 0 Td
(and)Tj
1.7291 0 Td
(induction)Tj
4.1386 0 Td
(of)Tj
1.0148 0 Td
(apoptosis,)Tj
4.2122 0 Td
(has)Tj
1.5421 0 Td
(become)Tj
-34.2026 -1.2983 Td
(the)Tj
1.4683 0 Td
(focus)Tj
2.3244 0 Td
(of)Tj
1.0148 0 Td
(tumor)Tj
2.7439 0 Td
(therapy)Tj
3.2485 0 Td
(research.)Tj
0.009 Tc
-9.6037 -1.3039 Td
(Ginsenoside)Tj
5.3177 0 Td
(Rg3)Tj
1.8199 0 Td
(is)Tj
0.873 0 Td
(the)Tj
1.508 0 Td
(main)Tj
2.3414 0 Td
(effective)Tj
3.6284 0 Td
(component)Tj
4.9322 0 Td
(of)Tj
1.0375 0 Td
(ginseng.)Tj
3.6283 0 Td
(It)Tj
0.8844 0 Td
(is)Tj
0.8788 0 Td
(the)Tj
1.508 0 Td
(fourth)Tj
2.8176 0 Td
(ring)Tj
1.9219 0 Td
(of)Tj
1.0431 0 Td
(three)Tj
-35.3364 -1.2983 Td
(saponins)Tj
3.8664 0 Td
(of)Tj
1.0431 0 Td
(the)Tj
1.508 0 Td
(Panax)Tj
2.727 0 Td
(ginseng)Tj
3.3902 0 Td
(saponin)Tj
3.4922 0 Td
(monomer,)Tj
4.5468 0 Td
(extracted)Tj
4.0025 0 Td
(from)Tj
2.2563 0 Td
(red)Tj
1.5818 0 Td
(ginseng)Tj
3.3902 0 Td
(by)Tj
1.2075 0 Td
(the)Tj
1.508 0 Td
(famous)Tj
-34.52 -1.2982 Td
(Japanese)Tj
3.7927 0 Td
(natural)Tj
3.1748 0 Td
(medicine)Tj
4.0251 0 Td
(chemist,)Tj
3.668 0 Td
(Kitagawa)Tj
4.0139 0 Td
(Hoon,)Tj
2.8403 0 Td
(in)Tj
1.0601 0 Td
(1980.)Tj
2.4151 0 Td
(ginsenoside)Tj
5.0627 0 Td
(Rg3's)Tj
2.4264 0 Td
(extraction)Tj
-32.4791 -1.2983 Td
(rate)Tj
1.7971 0 Td
(is)Tj
0.8731 0 Td
(0.003%,)Tj
3.4242 0 Td
(the)Tj
1.508 0 Td
(molecular)Tj
4.337 0 Td
(formula)Tj
3.5036 0 Td
(is)Tj
0.8731 0 Td
(C)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 369.9212 484.7244 cm
BT
/F6 1 Tf
1 TL
0.012 Tc
0 0 Td
(42)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 377.348 486.4251 cm
BT
/F6 1 Tf
1 TL
0.009 Tc
0 0 Td
(H)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 385.1149 484.7244 cm
BT
/F6 1 Tf
1 TL
0.012 Tc
0 0 Td
(72)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 392.485 486.4251 cm
BT
/F6 1 Tf
1 TL
0.009 Tc
0 0 Td
(O)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 400.0818 484.7244 cm
BT
/F6 1 Tf
1 TL
0.012 Tc
0 0 Td
(13)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 407.4519 486.4251 cm
BT
/F6 1 Tf
1 TL
0.009 Tc
0 0 Td
(,)Tj
0.4592 0 Td
(and)Tj
1.7688 0 Td
(the)Tj
1.508 0 Td
(molecular)Tj
4.337 0 Td
(weight)Tj
2.965 0 Td
(is)Tj
0.8731 0 Td
(785.01.)Tj
3.1407 0 Td
(As)Tj
1.2926 0 Td
(a)Tj
-37.0882 -1.3039 Td
(vasodepressor,)Tj
6.2476 0 Td
(ginsenosideRg3)Tj
6.6613 0 Td
(was)Tj
1.7405 0 Td
(the)Tj
1.508 0 Td
(first)Tj
1.8709 0 Td
(compound)Tj
4.6997 0 Td
(to)Tj
1.0545 0 Td
(be)Tj
1.1735 0 Td
(used)Tj
2.1146 0 Td
(for)Tj
1.423 0 Td
(anti-tumor)Tj
4.7735 0 Td
(treatment.)Tj
-33.2671 -1.2982 Td
(Its)Tj
1.2586 0 Td
(way)Tj
1.8312 0 Td
(of)Tj
1.0375 0 Td
(action)Tj
2.7779 0 Td
(involved)Tj
3.753 0 Td
(the)Tj
1.5081 0 Td
(prevention)Tj
4.7111 0 Td
(of)Tj
1.0432 0 Td
(tumor)Tj
2.8062 0 Td
(cell)Tj
1.6157 0 Td
(secretion)Tj
3.9571 0 Td
(of)Tj
1.0432 0 Td
(vascular)Tj
3.5773 0 Td
(growth)Tj
3.1521 0 Td
(factors,)Tj
-34.0722 -1.2983 Td
(interfering)Tj
4.6318 0 Td
(with)Tj
2.0523 0 Td
(the)Tj
1.508 0 Td
(interaction)Tj
4.7509 0 Td
(between)Tj
3.6169 0 Td
(endothelial)Tj
4.8131 0 Td
(cells)Tj
1.9899 0 Td
(and)Tj
1.7689 0 Td
(the)Tj
1.508 0 Td
(extracellular)Tj
5.3007 0 Td
(matrix,)Tj
3.1918 0 Td
(and)Tj
-35.1323 -1.3039 Td
(reducing)Tj
3.8778 0 Td
(the)Tj
1.508 0 Td
(microvessel)Tj
5.023 0 Td
(density)Tj
3.1918 0 Td
(in)Tj
1.0601 0 Td
(tumor)Tj
2.812 0 Td
(tissue.)Tj
2.7723 0 Td
(The)Tj
1.8197 0 Td
(use)Tj
1.576 0 Td
(of)Tj
1.0375 0 Td
(ginsenoside)Tj
5.0627 0 Td
(Rg3)Tj
1.8255 0 Td
(had)Tj
1.7461 0 Td
(no)Tj
1.3039 0 Td
(signifi-)Tj
-34.6164 -1.2983 Td
(cant)Tj
1.9729 0 Td
(effect)Tj
2.4435 0 Td
(on)Tj
1.3039 0 Td
(sex)Tj
1.508 0 Td
(hormone)Tj
4.0139 0 Td
(levels)Tj
2.4548 0 Td
(and)Tj
1.7688 0 Td
(thus,)Tj
2.228 0 Td
(no)Tj
1.2983 0 Td
(estrogen)Tj
3.7246 0 Td
(deficiency)Tj
4.3936 0 Td
(associated)Tj
4.388 0 Td
(side)Tj
1.8539 0 Td
(effects.)Tj
-33.3522 -1.2982 Td
(Ginsenoside)Tj
5.3121 0 Td
(Rg3)Tj
1.8199 0 Td
(is)Tj
0.873 0 Td
(the)Tj
1.5137 0 Td
(only)Tj
2.0239 0 Td
(tumor)Tj
2.812 0 Td
(angiogenesis)Tj
5.4482 0 Td
(inhibitor)Tj
3.8946 0 Td
(with)Tj
2.0523 0 Td
(clinical)Tj
3.1805 0 Td
(application)Tj
4.8245 0 Td
(in)Tj
-33.7547 -1.304 Td
(the)Tj
1.5081 0 Td
(world.)Tj
2.8573 0 Td
(At)Tj
1.2302 0 Td
(present,)Tj
3.4923 0 Td
(ginsenoside)Tj
5.0626 0 Td
(Rg3)Tj
1.8255 0 Td
(is)Tj
0.8731 0 Td
(mainly)Tj
3.067 0 Td
(used)Tj
2.1089 0 Td
(to)Tj
1.0545 0 Td
(inhibit)Tj
2.9934 0 Td
(the)Tj
1.508 0 Td
(recurrence)Tj
4.6601 0 Td
(and)Tj
1.7688 0 Td
(metasta-)Tj
-34.0098 -1.2982 Td
(sis)Tj
1.2473 0 Td
(of)Tj
1.0431 0 Td
(various)Tj
3.2315 0 Td
(malignant)Tj
4.3993 0 Td
(tumors)Tj
3.1805 0 Td
(after)Tj
2.1033 0 Td
(surgery,)Tj
3.5206 0 Td
(radiotherapy,)Tj
5.7485 0 Td
(and)Tj
1.7688 0 Td
(chemotherapy.)Tj
6.3439 0 Td
(It)Tj
0.8844 0 Td
(can)Tj
-33.4712 -1.2983 Td
(inhibit)Tj
2.9934 0 Td
(the)Tj
1.508 0 Td
(proliferation)Tj
5.4368 0 Td
(of)Tj
1.0375 0 Td
(tumor)Tj
2.812 0 Td
(vascular)Tj
3.5773 0 Td
(endothelial)Tj
4.8131 0 Td
(cells)Tj
1.9842 0 Td
(and)Tj
1.7688 0 Td
(the)Tj
1.508 0 Td
(formation)Tj
4.3767 0 Td
(of)Tj
1.0431 0 Td
(new)Tj
1.9163 0 Td
(blood)Tj
-34.7752 -1.2983 Td
(vessels)Tj
2.9424 0 Td
(by)Tj
1.2075 0 Td
(regulating)Tj
4.3937 0 Td
(some)Tj
2.3868 0 Td
(cytokine)Tj
3.7417 0 Td
(anti-angiogenic)Tj
6.6613 0 Td
(factors[)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(].)Tj
4.9152 0 Td
(Recently,)Tj
4.0025 0 Td
(Chinese)Tj
3.5263 0 Td
(research-)Tj
-33.7774 -1.3039 Td
(ers)Tj
1.4117 0 Td
(have)Tj
2.1146 0 Td
(found)Tj
2.6816 0 Td
(that)Tj
1.8311 0 Td
(ginsenoside)Tj
5.0627 0 Td
(Rg3)Tj
1.8255 0 Td
(can)Tj
1.6611 0 Td
(inhibit)Tj
2.9934 0 Td
(the)Tj
1.5079 0 Td
(development)Tj
5.5558 0 Td
(of)Tj
1.0432 0 Td
(endometriosis)Tj
6.0718 0 Td
(lesions)Tj
-33.7604 -1.2982 Td
(in)Tj
1.0602 0 Td
(rats,)Tj
1.9729 0 Td
(reduce)Tj
2.999 0 Td
(the)Tj
1.5081 0 Td
(volume)Tj
3.2768 0 Td
(of)Tj
1.0431 0 Td
(ectopic)Tj
3.1691 0 Td
(lesions,)Tj
3.2655 0 Td
(inhibit)Tj
2.9933 0 Td
(the)Tj
1.508 0 Td
(expression)Tj
4.5921 0 Td
(of)Tj
1.0432 0 Td
(VEGF,)Tj
3.016 0 Td
(and)Tj
1.7688 0 Td
(halter)Tj
-33.2161 -1.2983 Td
(angiogenesis[)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(].)Tj
7.3701 0 Td
(However,)Tj
4.1782 0 Td
(the)Tj
1.508 0 Td
(effect)Tj
2.4435 0 Td
(of)Tj
1.0431 0 Td
(the)Tj
1.5081 0 Td
(ginsenoside)Tj
5.0625 0 Td
(Rg3)Tj
1.8198 0 Td
(on)Tj
1.304 0 Td
(VEGFR-2)Tj
4.2632 0 Td
(and)Tj
1.7688 0 Td
(associated)Tj
-32.2693 -1.3039 Td
(signal)Tj
2.6192 0 Td
(transduction)Tj
5.4879 0 Td
(pathway)Tj
3.6623 0 Td
(remained)Tj
4.1386 0 Td
(unclear.)Tj
3.5263 0 Td
(Therefore,)Tj
4.5239 0 Td
(this)Tj
1.7235 0 Td
(study)Tj
2.4548 0 Td
(aims)Tj
2.1543 0 Td
(to)Tj
1.0488 0 Td
(investigate)Tj
-31.3396 -1.2983 Td
(the)Tj
1.5081 0 Td
(effect)Tj
2.4434 0 Td
(of)Tj
1.0375 0 Td
(ginsenoside)Tj
5.0626 0 Td
(Rg3)Tj
1.8255 0 Td
(on)Tj
1.2983 0 Td
(EMs)Tj
2.0863 0 Td
(treatment)Tj
4.2519 0 Td
(in)Tj
1.0602 0 Td
(rats)Tj
1.7347 0 Td
(and)Tj
1.7688 0 Td
(to)Tj
1.0545 0 Td
(investigate)Tj
4.6034 0 Td
(the)Tj
1.508 0 Td
(interaction)Tj
-31.2432 -1.2982 Td
(between)Tj
3.617 0 Td
(the)Tj
1.5081 0 Td
(ginsenoside)Tj
5.0626 0 Td
(Rg3)Tj
1.8255 0 Td
(and)Tj
1.7688 0 Td
(the)Tj
1.508 0 Td
(VEGFR-2)Tj
4.2633 0 Td
(mediated)Tj
4.0478 0 Td
(PI3K/Akt/mTOR)Tj
7.3757 0 Td
(signaling)Tj
3.9401 0 Td
(path-)Tj
-34.9169 -1.304 Td
(way.)Tj
2.0693 0 Td
(Ultimately,)Tj
4.8132 0 Td
(this)Tj
1.7235 0 Td
(study)Tj
2.4548 0 Td
(will)Tj
1.7177 0 Td
(contribute)Tj
4.5241 0 Td
(to)Tj
1.0488 0 Td
(the)Tj
1.508 0 Td
(development)Tj
5.5558 0 Td
(of)Tj
1.0375 0 Td
(a)Tj
0.669 0 Td
(new)Tj
1.9162 0 Td
(method)Tj
3.4015 0 Td
(for)Tj
1.423 0 Td
(early)Tj
-33.8624 -1.2982 Td
(diagnosis)Tj
4.0762 0 Td
(and)Tj
1.7688 0 Td
(prognosis)Tj
4.2406 0 Td
(of)Tj
1.0432 0 Td
(clinical)Tj
3.1804 0 Td
(EMs)Tj
2.0807 0 Td
(based)Tj
2.5398 0 Td
(on)Tj
1.2982 0 Td
(the)Tj
1.508 0 Td
(administration)Tj
6.3552 0 Td
(of)Tj
1.0375 0 Td
(an)Tj
1.2302 0 Td
(angiogenesis)Tj
-30.3588 -1.2983 Td
(inhibitor.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 195.9874 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Materials)Tj
4.5071 0 Td
(and)Tj
1.989 0 Td
(methods)Tj
/F0 1 Tf
-6.4961 -1.4976 Td
(Animals)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 161.0078 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(This)Tj
1.9842 0 Td
(study)Tj
2.3924 0 Td
(used)Tj
2.058 0 Td
(female)Tj
2.8573 0 Td
(Sprague-Dawley)Tj
6.7634 0 Td
(\(SD\))Tj
2.1089 0 Td
(rats,)Tj
1.9106 0 Td
(67)Tj
1.6894 0 Td
(weeks)Tj
2.6079 0 Td
(old,)Tj
1.7291 0 Td
(weighing)Tj
3.8664 0 Td
(between)Tj
3.5263 0 Td
(180)Tj
1.6498 0 Td
(and)Tj
-35.1437 -1.2982 Td
(200g)Tj
2.1089 0 Td
(each,)Tj
2.2564 0 Td
(raised)Tj
2.6022 0 Td
(in)Tj
1.0374 0 Td
(the)Tj
1.4684 0 Td
(Laboratory)Tj
4.6431 0 Td
(Animal)Tj
3.2201 0 Td
(Center)Tj
2.948 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(Shanghai)Tj
3.9004 0 Td
(Institute)Tj
3.583 0 Td
(of)Tj
1.0148 0 Td
(Planned)Tj
3.5093 0 Td
(Par-)Tj
-34.7752 -1.3039 Td
(enthood)Tj
3.5602 0 Td
(Research\(Certificate)Tj
8.2998 0 Td
(of)Tj
1.0148 0 Td
(Quality)Tj
3.1975 0 Td
(No:)Tj
1.6894 0 Td
(SCXK)Tj
2.6873 0 Td
([hu])Tj
1.9502 0 Td
(20130016\).)Tj
5.108 0 Td
(All)Tj
1.4003 0 Td
(animal)Tj
2.9707 0 Td
(tests)Tj
1.9615 0 Td
(were)Tj
-33.8397 -1.2983 Td
(conducted)Tj
4.4276 0 Td
(in)Tj
1.0318 0 Td
(accordance)Tj
4.7395 0 Td
(with)Tj
1.9956 0 Td
(the)Tj
0.83 0.64 0.02 0 k
1.4684 0 Td
(AVMA)Tj
3.1804 0 Td
(Guidelines)Tj
4.5241 0 Td
(for)Tj
1.3889 0 Td
(the)Tj
1.4684 0 Td
(Euthanasia)Tj
4.6204 0 Td
(of)Tj
1.0148 0 Td
(Animals:)Tj
3.8098 0 Td
(2013)Tj
-33.6697 -1.2983 Td
(Edition)Tj
0 g
([)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(].)Tj
5.0626 0 Td
(The)Tj
1.7801 0 Td
(study)Tj
2.3925 0 Td
(was)Tj
1.6951 0 Td
(approved)Tj
3.9741 0 Td
(by)Tj
1.1792 0 Td
(the)Tj
1.474 0 Td
(Animal)Tj
3.2202 0 Td
(Care)Tj
2.1089 0 Td
(and)Tj
1.7292 0 Td
(Use)Tj
1.7404 0 Td
(Committee)Tj
4.7452 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(Shanghai)Tj
-33.5846 -1.3039 Td
(Institute)Tj
3.5829 0 Td
(of)Tj
1.0148 0 Td
(Planned)Tj
3.5093 0 Td
(Parenthood)Tj
4.9209 0 Td
(Research)Tj
3.8041 0 Td
(\(number)Tj
3.7587 0 Td
(201504\).)Tj
4.1556 0 Td
(The)Tj
1.7858 0 Td
(rat's)Tj
1.8992 0 Td
(sample)Tj
3.0217 0 Td
(size)Tj
1.6837 0 Td
(was)Tj
1.7008 0 Td
(calcu-)Tj
-34.8375 -1.2982 Td
(lated)Tj
2.1486 0 Td
(according)Tj
4.1896 0 Td
(to)Tj
1.0261 0 Td
(Wei)Tj
1.8709 0 Td
(\(2010\)[)Tj
0.83 0.64 0.02 0 k
(13)Tj
0 g
(].)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 416.6362 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Ginsen)Tj
3.111 0 Td
(oside)Tj
2.5654 0 Td
(Rg3)Tj
2.0197 0 Td
(inhibits)Tj
3.2669 0 Td
(angiogenes)Tj
5.067 0 Td
(is)Tj
0.9284 0 Td
(in)Tj
0.9779 0 Td
(EMs)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01865)Tj
4.089 0 Td
(20)Tj
0 g
2.0906 0 Td
(November)Tj
4.7622 0 Td
(15,)Tj
1.5875 0 Td
(2017)Tj
32.5561 0 Td
(3)Tj
0.7654 0 Td
(/)Tj
ET
endstream
endobj
49 0 obj
<>stream
endstream
endobj
50 0 obj
<>stream
endstream
endobj
51 0 obj
<>stream
endstream
endobj
52 0 obj
<>stream
endstream
endobj
53 0 obj
<>stream
endstream
endobj
54 0 obj
<>stream
endstream
endobj
55 0 obj
<>stream
BT
66.402 0 Td
(16)Tj
ET
Q
endstream
endobj
56 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 11 0 R/Annots 60 0 R/Contents 61 0 R/TrimBox[0 0 612 792]>>
endobj
59 0 obj
<>stream
JFIF C
$, !$4.763.22:ASF:=N>22HbINVX]^]8EfmeZlS[]Y C**Y;2;YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY "
} !1AQa"q2#BR$3br
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz
w !1AQaq"2B #3Rbr
$4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ? (
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
e]#?2} jQմm^nr7!T= A$2
5wy} Ko-dAe@ɨQE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE g:MbַKyGyN>7e#+7[ѭu\r!@˶][=$R
x"1ҵjϧJe!G PM)4.Dr(J(Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@zmX{ט?+uKjj9_Q?zuexCl|/1J(P3J)RhX^7O2е jjᅡ<3K.7IcY#`*rQE( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( oXdL.9C/߅#k .I[&7.Pf)qO4VW@A uy;ɥk1JGr=T֝ċE m>y?룄Y,wTWu^iZ<i ܊XTؑ \=^ 0 I :?E~{TWv<
s#?Ҁ:[hVߨ ˸EwS ?ҟo Fa&j[_DǗq = 4+7ćvi/.sj/I<]} q͏Ͳ+Сq1=B *9[`^-|oݎQ@((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((̨2I)P6IqW@<#C[oO,GC?*{gv5>$s' ,5^]]?sa@h